BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16850393)

  • 1. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
    Peng SX; Ritchie DM; Cousineau M; Danser E; Dewire R; Floden J
    J Pharm Sci; 2006 Sep; 95(9):1984-93. PubMed ID: 16850393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
    Li X; Choi JS
    Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
    Bedada SK; Appani R; Boga PK
    Drug Dev Ind Pharm; 2017 Jun; 43(6):932-938. PubMed ID: 28102715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fruit juices on the oral bioavailability of fexofenadine in rats.
    Kamath AV; Yao M; Zhang Y; Chong S
    J Pharm Sci; 2005 Feb; 94(2):233-9. PubMed ID: 15570603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
    Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
    Dresser GK; Bailey DG; Leake BF; Schwarz UI; Dawson PA; Freeman DJ; Kim RB
    Clin Pharmacol Ther; 2002 Jan; 71(1):11-20. PubMed ID: 11823753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
    Lee CK; Choi JS
    Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
    van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
    J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
    Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R
    Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cysteine on the pharmacokinetics of paclitaxel in rats.
    Lee YK; Han SY; Chin YW; Choi YH
    Arch Pharm Res; 2012 Mar; 35(3):509-16. PubMed ID: 22477198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats.
    Jin J; Bi H; Hu J; Zhong G; Zhao L; Huang Z; Huang M
    Biopharm Drug Dispos; 2010 May; 31(4):264-8. PubMed ID: 20437465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
    Choi BC; Choi JS; Han HK
    Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment.
    Olsén L; Ingvast-Larsson C; Larsson P; Broström H; Bondesson U; Sundqvist M; Tjälve H
    J Vet Pharmacol Ther; 2006 Apr; 29(2):129-35. PubMed ID: 16515667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
    Varma MV; Panchagnula R
    Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
    Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
    Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketoconazole on digoxin absorption and disposition in rat.
    Salphati L; Benet LZ
    Pharmacology; 1998 Jun; 56(6):308-13. PubMed ID: 9654217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.
    Jin MJ; Han HK
    J Food Sci; 2010 Apr; 75(3):H93-6. PubMed ID: 20492299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
    Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
    Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.
    Bedada SK; Boga PK
    Eur J Clin Pharmacol; 2017 Mar; 73(3):343-349. PubMed ID: 27981349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.